Photo by nci from unsplash
Targeting inflammation is increasingly recognized as a novel therapeutic option in the management of type 2 diabetes and prevention of recurrent cardiovascular disease (CVD). In CANTOS (Canakinumab Anti-inflammatory Thrombosis Outcomes… Click to show full abstract
Targeting inflammation is increasingly recognized as a novel therapeutic option in the management of type 2 diabetes and prevention of recurrent cardiovascular disease (CVD). In CANTOS (Canakinumab Anti-inflammatory Thrombosis Outcomes Study), canakinumab had similar magnitude effects on major
Keywords:
pathways cvd;
inflammatory pathways;
broad spectrum;
cvd diabetes;
spectrum versus;
diabetes broad
Journal Title: Journal of the American College of Cardiology
Year Published: 2018
Link to full text (if available)
Share on Social Media: Sign Up to like & get
recommendations!
Journal Title: Journal of the American College of Cardiology
Year Published: 2018
Link to full text (if available)
Share on Social Media: Sign Up to like & get
recommendations!